Cipla Q1 Net Profit Falls 39% to ₹785.55 Crore on Weak North America Sales
Indian drugmaker Cipla reported a 39% decline in consolidated net profit for the quarter ended June 2026, falling to ₹785.55 crore from ₹1,291.61 crore a year earlier, driven by lower sales in the key North America market. Total revenue from operations rose over 2% to ₹7,119.28 crore, supported by a 12% increase in the India business to ₹3,452 crore. However, the U.S. business revenue dropped to ₹1,532 crore from ₹1,933 crore. Managing Director and Global CEO Achin Gupta expressed confidence in continued sequential growth in North America, citing the upcoming product pipeline. The company's South Africa private business grew faster than the market, while Emerging Markets and Europe saw 5% year-on-year revenue growth in dollar terms. Cipla plans to focus on growing key markets, building flagship brands, investing in the future pipeline, and resolving regulatory issues.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection